Response to temozolomide in second-line treatment of recurrent nonsmall cell lung carcinoma: Case report

Cancer Investigation

Volumn 23, Issue 2, 2005, Pages 134-137

  Somer, Robert A ^a   Langer, Corey J ^b  

^a Department of Anesthesiology   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Chemotherapy; Clinical response; Nonsmall cell lung cancer; Recurrent disease; Temozolomide

Indexed keywords

CISPLATIN; COTRIMOXAZOLE; IMMUNOGLOBULIN; IRINOTECAN; LEVOFLOXACIN; STEROID; TEMOZOLOMIDE;

ADULT; ANOREXIA; ARTICLE; CANCER GRADING; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DIZZINESS; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHADENOPATHY; PALLIATIVE THERAPY; PLEURA EFFUSION; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; STREPTOCOCCUS PNEUMONIA;

EID: 16244364073     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1081/CNV-50449     Document Type: Article

References (17)

1. Mountain, C.F. A new international staging system for lung cancer. Chest 1986, 89 (suppl), S225-S233.
2. Kelly, K.; Crowley, J.; Bunn, P.A., Jr.; et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 2001, 19, 3210-3218.
3. Huisman, C.; Smit, E.F.; Giaccone, G.; Postmus, P.E. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J. Clin. Oncol. 2000, 18, 3722-3730.
4. Adonizio, C.S.; Babb, J.S.; Maiale, C.; et al. Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients. Clin. Lung Cancer 2002, 3, 254-258.
5. Newlands, E.S.; Blackledge, G.R.; Slack, J.A.; et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer 1992, 65, 287-291.
6. Stupp, R.; Ostermann, S.; Leyvraz, S.; Csajka, C.; Buclin, T.; Decosterd, L.A. Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration [abstract]. Proc. Am. Soc. Clin. Oncol. 2001, 20, 59a.
7. Yung, W.K.; Prados, M.D.; Yaya-Tur, R.; et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J. Clin. Oncol. 1999, 17, 2762-2771.
8. Yung, W.K.; Albright, R.E.; Olson, J.; et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 2000, 83, 588-593.
9. Loeffler, J.S.; Patchell, R.A.; Sawaya, R. Treatment of metastatic cancer. In Cancer: Principles and Practice of Oncology, 5th Ed.; De Vita, V.T.J., Hellman, S., Rosenberg, S.A., Eds.; Lippincott-Raven Publishers: Philadelphia, PA, 1997; 2523-2536.
10. Christodoulou, C.; Bafaloukos, D.; Kosmidis, P.; et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann. Oncol. 2001, 12, 249-254.
11. Antonadou, D.; Paraskevaidis, M.; Sarris, G.; et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J. Clin. Oncol. 2002, 20, 3644-3650.
12. American Cancer Society. Cancer Facts and Figures 2002; American Cancer Society: Atlanta, GA, 2002.
13. Greenlee, R.T.; Murray, T.; Bolden, S.; Wingo, P.A. Cancer statistics, 2000. CA Cancer J. Clin. 2000, 50, 7-33.
14. Clark, R.; Ihde, D.C. Small-cell lung cancer: treatment progress and prospects. Oncology (Huntingt.) 1998, 12, pp. 647-658, 661-663.
15. Shepherd, FA. Chemotherapy for advanced non-small-cell lung cancer: modest progress, many choices. J. Clin. Oncol. 2000, 18, 35S-38S.
16. Schiller, J.H.; Harrington, D.; Belani, C.P.; et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346, 92-98.
17. Su, Y.B.; Sejean, S.; Krown, S.E.; Livingston, P.O.; Wolchok, J.D.; Quinn, C.; Williams, L.; Foster, T.; Sepkowitz, K.A.; Chapman, P.B. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J. Clin. Oncol. 2004, 22, 610-616.